• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Paul G. Richardson, MD

R.J. Corman Professor, Department of Medicine, Harvard Medical School

Contact Info

Paul Richardson
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Mayer 2
Phone: 617-632-2127
Fax: 617-632-6624
paul_richardson@dfci.harvard.edu

Assistant

Sarah Leist
Administrative Assistant - Clinical
Adult Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Phone: 617-632-2127
sleist@partners.org
Michelle Maglio
Administrative Assistant - Academic
Adult Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Phone: 617-632-4893
michelle_maglio@dfci.harvard.edu

DF/HCC Program Affiliation

Translational Pharmacology and Early Therapeutic Trials
Lymphoma and Myeloma
Angiogenesis, Invasion and Metastasis

Research Abstract

Our research focus has been the study of small molecules - thalidomide and its derivatives and the novel proteasome inhibitor (PS341) - as new treatments for multiple myeloma. Under the overall direction and mentorship of Dr. Kenneth Anderson, Dr. Richardson is leading several novel, biologically derived translational efforts in multiple myeloma. These have been focused in the clinical study of new drugs in the phase 1 and phase 2 settings; specifically thalidomide, the thalidomide analog IMiD 3 (also known as CC-5013 or CDC-501), 2-methoxy estradiol (2-ME2), and the first-in-class proteasome inhibitor, PS 341 (also known as MLN-341 or Velcade).



Research in high-dose chemotherapy and transplantation-related toxicities including hepatic veno-occlusive disease (VOD) has resulted in the development of the novel agent defibrotide as a therapy for severe hepatic VOD. This has led to further research in endothelial cell injury during high-dose therapy, related treatment strategies, and the study of vascular damage affecting other organ structures including mucosa.

Publications

View All Publications